ES2996888T3 - Pic1 inhibition of myeloperoxidase oxidative activity in an animal model - Google Patents

Pic1 inhibition of myeloperoxidase oxidative activity in an animal model Download PDF

Info

Publication number
ES2996888T3
ES2996888T3 ES19738307T ES19738307T ES2996888T3 ES 2996888 T3 ES2996888 T3 ES 2996888T3 ES 19738307 T ES19738307 T ES 19738307T ES 19738307 T ES19738307 T ES 19738307T ES 2996888 T3 ES2996888 T3 ES 2996888T3
Authority
ES
Spain
Prior art keywords
pic1
dpeg24
mpo
antibody
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19738307T
Other languages
English (en)
Spanish (es)
Inventor
Neel Krishna
Kenji Cunnion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Realta Holdings LLC
Original Assignee
Realta Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Realta Holdings LLC filed Critical Realta Holdings LLC
Application granted granted Critical
Publication of ES2996888T3 publication Critical patent/ES2996888T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Wood Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
ES19738307T 2018-01-09 2019-01-08 Pic1 inhibition of myeloperoxidase oxidative activity in an animal model Active ES2996888T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862615183P 2018-01-09 2018-01-09
US201862681458P 2018-06-06 2018-06-06
US201862746649P 2018-10-17 2018-10-17
PCT/US2019/012659 WO2019139886A1 (en) 2018-01-09 2019-01-08 Pic1 inhibition of myeloperoxidase oxidative activity in an animal model

Publications (1)

Publication Number Publication Date
ES2996888T3 true ES2996888T3 (en) 2025-02-13

Family

ID=67140101

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19738307T Active ES2996888T3 (en) 2018-01-09 2019-01-08 Pic1 inhibition of myeloperoxidase oxidative activity in an animal model

Country Status (12)

Country Link
US (6) US11135272B2 (https=)
EP (2) EP3740074B1 (https=)
JP (2) JP7031011B2 (https=)
KR (2) KR20220104268A (https=)
CN (1) CN112512548A (https=)
AU (2) AU2019207508B2 (https=)
CA (1) CA3086407A1 (https=)
ES (1) ES2996888T3 (https=)
IL (2) IL287308B2 (https=)
MX (3) MX2020007098A (https=)
SG (1) SG11202006063RA (https=)
WO (1) WO2019139886A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10947279B2 (en) 2015-06-26 2021-03-16 Realta Holdings, Llc Synthetic peptide compounds and methods of use
EP3740074B1 (en) 2018-01-09 2024-11-06 ReAlta Holdings, LLC Pic1 inhibition of myeloperoxidase oxidative activity in an animal model
IL301441A (en) * 2020-09-30 2023-05-01 Realta Life Sciences Inc Peptides and methods of use
WO2022094367A1 (en) * 2020-11-02 2022-05-05 Realta Life Sciences, Inc. Peptides and methods of use
WO2022094372A1 (en) * 2020-11-02 2022-05-05 Realta Life Sciences, Inc. Peptides and methods of use
CA3194447A1 (en) * 2020-11-09 2022-05-12 Neel K. Krishna Peptide formulations and methods of use
WO2022179937A1 (en) * 2021-02-26 2022-09-01 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Anti-cleaved histone h3 monoclonal antibody that specifically recognizes neutrophil extracellular traps
JP2024522988A (ja) * 2021-06-01 2024-06-25 レアルタ ライフ サイエンシズ インコーポレイテッド ペプチドおよび使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625049A (en) 1993-05-12 1997-04-29 Us Health Nucleic acids encoding human astrovirus serotype 2
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
AU3066699A (en) 1998-03-03 1999-09-20 Johns Hopkins University, The Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
AU2729400A (en) 1999-01-19 2000-08-07 James Daly Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease
US6696562B1 (en) 2000-07-10 2004-02-24 The United States Of America As Represented By The Secretary Of Agriculture Avian astrovirus
US20070012617A1 (en) 2003-09-05 2007-01-18 Sadakatsu Suzuki Method for producing micro-porous film of thermoplastic resin
WO2005023296A1 (en) 2003-09-05 2005-03-17 University Of Louisville Research Foundation, Inc. Treatment of rheumatic diseases
WO2005023195A2 (en) 2003-09-05 2005-03-17 University Of Louisville Research Foundation, Inc. Treatment of spinal cord injury
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
US7381524B2 (en) 2003-10-10 2008-06-03 Wisconsin Alumni Research Foundation Method to detect antibodies specific for type-2 turkey astrovirus
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2007145806A2 (en) 2006-06-15 2007-12-21 Eastern Virginia Medical School Methods for regulating complement cascade proteins using astrovirus coat protein and derivatives thereof
US7956161B2 (en) 2007-04-11 2011-06-07 Pestka Biomedical Laboratories, Inc. Interferons of rhesus and cynomolgus origin and uses thereof
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
EP2561367A1 (en) 2010-04-22 2013-02-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations
US10005818B2 (en) 2010-07-21 2018-06-26 Realta Holdings, Llc Derivative peptide compounds and methods of use
ES2688589T3 (es) 2010-07-21 2018-11-05 Eastern Virginia Medical School Compuestos peptídicos para regular el sistema del complemento
CA2867593A1 (en) 2012-03-16 2013-09-19 Belrose Pharma, Inc. Polymeric conjugates of c-1 inhibitors
ES2875498T3 (es) * 2015-06-26 2021-11-10 Realta Holdings Llc Compuestos de péptidos sintéticos y procedimientos de uso
EP3740074B1 (en) 2018-01-09 2024-11-06 ReAlta Holdings, LLC Pic1 inhibition of myeloperoxidase oxidative activity in an animal model

Also Published As

Publication number Publication date
IL287308B2 (en) 2024-03-01
EP3740074A1 (en) 2020-11-25
KR102420552B1 (ko) 2022-07-13
WO2019139886A1 (en) 2019-07-18
MX2020007098A (es) 2020-11-11
IL287308A (en) 2021-12-01
JP7341268B2 (ja) 2023-09-08
IL275867A (en) 2020-08-31
EP4464716A3 (en) 2025-02-19
JP2021509916A (ja) 2021-04-08
EP4464716A2 (en) 2024-11-20
MX2025009081A (es) 2025-09-02
US11712462B2 (en) 2023-08-01
US20210252113A1 (en) 2021-08-19
EP3740074B1 (en) 2024-11-06
US11135272B2 (en) 2021-10-05
US20260021164A1 (en) 2026-01-22
AU2024205230A1 (en) 2024-09-05
AU2019207508B2 (en) 2024-05-02
KR20220104268A (ko) 2022-07-26
JP7031011B2 (ja) 2022-03-07
EP3740074A4 (en) 2021-10-13
US20200230212A1 (en) 2020-07-23
US20250177492A1 (en) 2025-06-05
IL275867B (en) 2022-01-01
SG11202006063RA (en) 2020-07-29
US11020460B2 (en) 2021-06-01
US20190209660A1 (en) 2019-07-11
JP2022068323A (ja) 2022-05-09
CA3086407A1 (en) 2019-07-18
US12257290B2 (en) 2025-03-25
US20230321201A1 (en) 2023-10-12
CN112512548A (zh) 2021-03-16
KR20200138168A (ko) 2020-12-09
AU2019207508A1 (en) 2020-07-09
MX2025009095A (es) 2025-11-03
IL287308B1 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
ES2996888T3 (en) Pic1 inhibition of myeloperoxidase oxidative activity in an animal model
Hair et al. Inhibition of immune complex complement activation and neutrophil extracellular trap formation by peptide inhibitor of complement C1
Lesher et al. Properdin in complement activation and tissue injury
JP2018524402A (ja) 合成ペプチド化合物及び使用方法
Stenson et al. The complement system in pediatric acute kidney injury
US20220096592A1 (en) Pic1 variants with improved solubility and methods of using the same
US20220175886A1 (en) Net stabilization as a therapy for sepsis
Krishna et al. The EPICC family of anti-inflammatory peptides: next generation peptides, additional mechanisms of action, and in vivo and ex vivo efficacy
ES2883952T3 (es) Clusterina para su uso en el tratamiento de microangiopatías trombóticas
Yin et al. Histone neutralization protects the ischemic brain against stroke-associated pneumonia
Davidsson Priming and activation of neutrophils from blood and tissue
ES2398660T3 (es) Uso de iones ferrosos para incrementar la inmunorreactividad de las preparaciones de inmunoglobulinas
Mannes Lessons from and for complement therapeutics: Novel mechanistic insights into terminal pathway activation and its linkage to thrombosis
Nyakundi The Impact of Hemoglobin Oxidation in Nlrp3 Inflammasome Activation Upon Intravascular Hemolysis
Kotimaa Analysis of systemic complement in experimental renal injury and disease
Jouni Anti-protamine/heparin antibodies: Molecular and functional assessment of novel approaches to inhibit antibody-mediated platelet destruction
Yuen Properdin Binds Pseudomnas aeruginosa and is Required for Neutrophil Extracellular Trap Mediated Activation of Complement Alternative Pathway